Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review
Therapeutic Advances in Musculoskeletal Disease, Volume 13, Year 2021
Notification
URL copied to clipboard!
Description
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu’s arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZMONO) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZCOMBO) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5–50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0–31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5–50.0) to 5.0 (0.0–5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0–14.0) months. Twenty-three (42.6%) patients were on TCZMONO and 31 (57.4%) on TCZCOMBO: MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZCOMBO were younger [38.0 (27.0–46.0) versus 45.0 (38.0–57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0–38.0) versus 6.0 (1.0–23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7–5.6) versus 1.3 (0.3–3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin. © The Author(s), 2021.
Authors & Co-Authors
Prieto-Pena, Diana
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Narváez, Javier A.
Spain, Barcelona
Hospital Universitari de Bellvitge
Solans-Laqué, Roser
Spain, Barcelona
Hospital Universitari Vall D'hebron
Callejas-Rubio, José Luís
Spain, Granada
Hospital Universitario San Cecilio
Fernández-Díaz, Carlos
Spain, Madrid
Instituto de Investigación Sanitaria Hospital Universitario de la Princesa
Rubio, Esteban Rabadán
Spain, Sevilla
Hospital Universitario Virgen Del Rocío
Fernández Carballido, C.
Spain, Alicante
Hospital Universitario San Juan
Melchor, Sheila
Spain, Madrid
Hospital Universitario 12 de Octubre
Romero-Yuste, Susana María
Spain, Pontevedra
Complejo Hospitalario Universitario de Pontevedra
Álvarez Rivas, Noelia
Spain, Aviles
Hospital Universitario San Agustín
Loricera, Javier
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Atienza-Mateo, Belén
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Castañeda, Santos
Spain, Madrid
Instituto de Investigación Sanitaria Hospital Universitario de la Princesa
González-Gay, Miguel Ángel
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Blanco-Alonso, Ricardo
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Statistics
Citations: 7
Authors: 15
Affiliations: 25
Identifiers
Doi:
10.1177/1759720X211020917
ISSN:
1759720X
Study Approach
Systematic review
Participants Gender
Male
Female